EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Randomized controlled pilot study: effect of carrageenan emulsifier on inflammation and gastrointestinal symptoms in quiescent ulcerative colitis

Reijo Laatikainen, Markku Lehto, Noora Mäkelä-Salmi, Markku Hillilä, Per-Henrik Groop, Hanne Salmenkari

Food & Nutrition Research · 30.10.2023 · 67

DOI: 10.29219/fnr.v67.9575 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Food & Nutrition Research, online erschienen am 30.10.2023. Verfasst von Reijo Laatikainen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Booston Oy Ltd, Helsinki, Finland. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Animal models have provided some evidence of the pro-inflammatory effects of the commonly used emulsifier carrageenan. However, the effects of food-grade carrageenan among people with ulcerative colitis (UC) are largely unknown.

Methods

A randomized, placebo-controlled cross-over study comparing high molecular carrageenan and oat-based beta-glucan preparation (placebo) among patients (n = 7) with quiescent UC was performed. Primary endpoint was Simple Clinical Colitis Activity Index (SCCAI) at the end of the treatment (7th day). Secondary analyses included biochemical biomarkers of inflammation, intestinal permeability, detoxification of intestinal lipopolysaccharide (LPS), and gastrointestinal symptoms measured by visual analog scale.

Results

There were no statistically significant differences in SCCAI or any biochemical markers between carrageenan and placebo periods, nor were there any significant differences when comparing either period to baseline. Gastrointestinal symptoms were higher during the placebo period; the sum of all symptoms and borborygmi was statistically significantly higher at the end of the placebo period than at the end of the carrageenan period (20.8 ± 18.6 vs. 13.3 ± 16.4; P = 0.031, and 29.7 ± 28.6 vs. 17.9 ± 23.6; P = 0.016).

Conclusions

Our study suggests that at least short-term usage of food-grade carrageenan is safe among people with UC, but given the limitations of the current study, robust human studies are still urgently needed.

Schlagwörter

Stichwörter der Autor:innen

IBDcarrageenanemulsifierinflammatory bowel diseaseulcerative colitis

Autor:innen und Institutionen

  • Booston Oy Ltd, Helsinki, Finland.
  • Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
  • Department of Food and Nutrition, University of Helsinki, Helsinki, Finland.
  • Clinic of Gastroenterology, University of Helsinki and Helsinki University, Hospital Jorvi, Espoo, Finland.
  • Abdominal Center, Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Zitieren

APA

Laatikainen, R., Lehto, M., Mäkelä-Salmi, N., Hillilä, M., Groop, P. H., & Salmenkari, H. (2023). Randomized controlled pilot study: effect of carrageenan emulsifier on inflammation and gastrointestinal symptoms in quiescent ulcerative colitis. Food & Nutrition Research, 67. https://doi.org/10.29219/fnr.v67.9575

Vancouver

Laatikainen R, Lehto M, Mäkelä-Salmi N, Hillilä M, Groop PH, Salmenkari H. Randomized controlled pilot study: effect of carrageenan emulsifier on inflammation and gastrointestinal symptoms in quiescent ulcerative colitis. Food & Nutrition Research. 2023;67. doi:10.29219/fnr.v67.9575

BibTeX
@article{Laatikainen2023,
  author = {Laatikainen, Reijo and Lehto, Markku and Mäkelä-Salmi, Noora and Hillilä, Markku and Groop, Per-Henrik and Salmenkari, Hanne},
  title = {Randomized controlled pilot study: effect of carrageenan emulsifier on inflammation and gastrointestinal symptoms in quiescent ulcerative colitis},
  journal = {Food & Nutrition Research},
  year = {2023},
  volume = {67},
  doi = {10.29219/fnr.v67.9575}
}
Kostenlos starten →